



Karyopharm Therapeutics  
Investor Relations Department  
85 Wells Ave, 2nd floor  
Newton, MA 02459  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: KPTI

|               |                            |
|---------------|----------------------------|
| Last Trade:   | 11.01                      |
| Trade Time:   | 4:00 PM ET<br>Oct 19, 2017 |
| Change:       | -0.32  (-2.824%)           |
| Day Range     | 10.94 - 11.36              |
| 52-Week Range | 6.27 - 14.63               |
| Volume        | 106,666                    |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

### Corporate Profile

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). In addition to single-agent and combination activity against a variety of human cancers, SINE™ compounds have also shown biological activity in models of neurodegeneration, inflamma... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

- Oct 12, 2017*  
[Karyopharm and Ono Pharmaceutical Co. Ltd. Sign Exclusive License Agreement to Develop and Commercialize Selinexor and KPT-8602 in Japan and Other Countries in Asia](#)
- Sep 20, 2017*  
[Karyopharm Announces Successful Outcome from Phase 2 Portion of Phase 2/3 SEAL Study Evaluating Selinexor in Patients with Previously Treated Advanced Dedifferentiated Liposarcoma](#)
- Sep 12, 2017*  
[Karyopharm Appoints Michael Falvey as Chief Financial Officer, Adds New Clinical Strategy and Human Resources Executives and Reports Inducement Grant Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)
- Sep 8, 2017*  
[Karyopharm Announces Presentation of Selinexor and KPT-9274 Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting](#)
- Aug 30, 2017*  
[Karyopharm Announces the Presentation of Selinexor and KPT-9274 Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting](#)

### Financials [\[ View all \]](#)

- [Second Quarter Financial Results](#)
- Mar 16, 2017*  
[Annual Report \(10-K\)](#)
- Apr 28, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Aug 8, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 4, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 7, 2016*  
[Quarterly Report \(10-Q\)](#)

